In Search of Pharma ’s Moore’s Law

Artificial Intelligence (AI) has made great strides in the past five years. We are probably using an AI-based system without even realizing it in our daily lives today. There is a lot of active research going on in AI in both academia and in the pharma industry. Within pharma, several opportunities open up as we think of AI making an impactful difference; lead candidate identification, drug development, compound repurposing, clinical trials, post approval, commercial markets, etc. Let us look at one area closely, that of planning and conduct of clinical trials.Costs of bringing a drug to the market over the last three decades.Moore ' s lore In my view, if there is one area that is ripe for disruption, it is this one. With the rising cost of clinical trials and associated processes, drug development costs and time have exponentially gone up over the last thirty years, from approximately $150m in 1970 to about $2.6bn this decade.1,2In 1965, Gordon Moore from Silicon Valley famously stated that the number of transistors in an integrated circuit would double every year, a phenomenon known as Moore ’s Law. Collectively, the semiconductor industry has proved him correct for several decades, dramatically increasing in power and decreasing in relative cost at an exponential rate. What is pharma ’s own Moore’s Law? Can AI-enabled technology help pharma to continuously ‘learn’ from its own clinical trials and that of peers to bring recursive savings in both time and cost? C...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news